GH Research PLC(GHRS)Earnings, Financials & Key Ratios
GHRS•NASDAQ
$22.44
$1.39B mkt cap·Price updated May 6, 2026
AboutGH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.Show more
- Revenue$0
- EBITDA-$60M-20.7%
- Net Income-$48M-23.9%
- EPS (Diluted)-0.79-5.3%
- ROE-21.04%-7.5%
- ROIC-80.72%-135.6%
- Debt/Equity0.00-47.5%
- Interest Coverage-131.05-141.5%
GHRS Key Insights
GH Research PLC (GHRS) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 90 (top 10%)
✗Weaknesses
- ✗Profits declining 155.2% over 5 years
- ✗Weak Piotroski F-Score: 3/9
- ✗Shares diluted 17.3% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
GHRS Price & Volume
GH Research PLC (GHRS) stock price & volume — 10-year historical chart
Loading chart...
GHRS Growth Metrics
GH Research PLC (GHRS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-23.86%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-6.67%
Return on Capital
10 Years-26.24%
5 Years-18.3%
3 Years-23.07%
Last Year-26.43%
GHRS Recent Earnings
GH Research PLC (GHRS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)
Q2 2026Latest
Mar 5, 2026EPS
$0.23
Est $0.29
+20.7%
Revenue
—
Q4 2025
Nov 6, 2025EPS
$0.23
Est $0.23
+0.0%
Revenue
—
Q3 2025
Aug 7, 2025EPS
$0.15
Est $0.22
+31.8%
Revenue
—
Q2 2025
May 8, 2025EPS
$0.19
Est $0.61
+68.9%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 5, 2026 | $0.23vs $0.29+20.7% | — |
| Q4 2025 | Nov 6, 2025 | $0.23vs $0.23+0.0% | — |
| Q3 2025 | Aug 7, 2025 | $0.15vs $0.22+31.8% | — |
| Q2 2025 | May 8, 2025 | $0.19vs $0.61+68.9% | — |
Based on last 12 quarters of dataView full earnings history →
GHRS Peer Comparison
GH Research PLC (GHRS) competitors in Neuroscience and Psychiatry Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 CMPS | 937.8M | 9.76 | -3.17 | -335.93% | ||||
 ATAI | 1B | 4.17 | -4.48 | -1.91% | -51.09% | -96.43% | 0.21 | |
 MNMD | 2.04B | 20.69 | -10.04 | -55.3% | ||||
 CYBN | 303.86M | 6.09 | -13.66 | -81% | ||||
 NRXP | 84.43M | 3.05 | -2.28 | -157.28% | ||||
 ACAD | 3.68B | 21.48 | 9.38 | 11.87% | 36.49% | 41.9% | 0.04 | |
 AXSM | 11.46B | 222.63 | -60.50 | 65.55% | -26.59% | -260.01% | 2.73 | |
 INVA | 1.91B | 22.52 | 6.82 | 18.52% | 118.91% | 46.47% | 0.23 |
Compare GHRS vs Peers
GH Research PLC (GHRS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
GHRS Income Statement
GH Research PLC (GHRS) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 335K |
| COGS % of Revenue | - | - | - | - | - | - | - |
| Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | -335K▲ 0% |
| Gross Margin % | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | - | - |
| Operating Expenses | 310K | 446K | 15.1M | 30.55M | 41.22M | 50.31M | 60.34M |
| OpEx % of Revenue | - | - | - | - | - | - | - |
| Selling, General & Admin | 14K | 108K | 6.54M | 10.06M | 11.12M | 15M | 21.61M |
| SG&A % of Revenue | - | - | - | - | - | - | - |
| Research & Development | 296K | 338K | 8.55M | 20.48M | 29.82M | 35.02M | 38.73M |
| R&D % of Revenue | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 5K | 14K | 280K | 294K | 0 |
| Operating Income | -310K▲ 0% | -446K▼ 43.9% | -15.1M▼ 3285.7% | -30.55M▼ 102.3% | -41.22M▼ 34.9% | -50.31M▼ 22.1% | -60.68M▼ 20.6% |
| Operating Margin % | - | - | - | - | - | - | - |
| Operating Income Growth % | - | -43.87% | -3285.65% | -102.34% | -34.92% | -22.05% | -20.6% |
| EBITDA | 0 | 0 | -15.08M | -30.51M | -40.91M | -50M | -60.34M |
| EBITDA Margin % | - | - | - | - | - | - | - |
| EBITDA Growth % | - | - | - | -102.29% | -34.09% | -22.22% | -20.69% |
| D&A (Non-Cash Add-back) | 310K | 446K | 19K | 47K | 315K | 315K | 335K |
| EBIT | -310K | -446K | -9.19M | -22.46M | -35.52M | -38.91M | -60.68M |
| Net Interest Income | 0 | 0 | -8.99K | 0 | 1.17M | 1.91M | 2.16M |
| Interest Income | 0 | 0 | 9 | - | 1.89M | 2.63M | 2.63M |
| Interest Expense | 0 | 0 | 9K | - | 723K | 717K | 463K |
| Other Income/Expense | 0 | 0 | 5.9M | 8.1M | 5.63M | 11.35M | 12.42M |
| Pretax Income | -310K▲ 0% | -446K▼ 43.9% | -9.2M▼ 1963.2% | -22.46M▼ 144.0% | -35.59M▼ 58.5% | -38.96M▼ 9.5% | -48.26M▼ 23.9% |
| Pretax Margin % | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -310K▲ 0% | -446K▼ 43.9% | -9.2M▼ 1963.2% | -22.46M▼ 144.0% | -35.59M▼ 58.5% | -38.96M▼ 9.5% | -48.26M▼ 23.9% |
| Net Margin % | - | - | - | - | - | - | - |
| Net Income Growth % | - | -43.87% | -1963.23% | -144.03% | -58.47% | -9.48% | -23.86% |
| Net Income (Continuing) | -310K | -446K | -9.2M | -22.46M | -35.59M | -38.96M | -48.26M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.01▲ 0% | -0.01▼ 32.4% | -0.18▼ 1124.5% | -0.14▲ 22.2% | -0.68▼ 385.7% | -0.75▼ 10.3% | -0.79▼ 5.3% |
| EPS Growth % | - | -32.43% | -1124.49% | 22.22% | -385.71% | -10.29% | -5.33% |
| EPS (Basic) | -0.01 | -0.01 | -0.18 | -0.14 | -0.68 | -0.75 | -0.79 |
| Diluted Shares Outstanding | 28M | 30.37M | 52.02M | 52.02M | 52.02M | 52.03M | 61.04M |
| Basic Shares Outstanding | 28M | 30.37M | 52.02M | 52.02M | 52.02M | 52.03M | 61.04M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
GHRS Balance Sheet
GH Research PLC (GHRS) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 504K | 5.91M | 279.84M | 168.54M | 164.09M | 154.22M | 285.98M |
| Cash & Short-Term Investments | 498K | 5.89M | 276.78M | 165.96M | 161.56M | 149.32M | 280.71M |
| Cash Only | 498K | 5.89M | 276.78M | 165.96M | 78.42M | 100.79M | 246.25M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 83.14M | 48.53M | 34.46M |
| Accounts Receivable | 0 | 0 | 48K | 90K | 178K | 1.73M | 1.29M |
| Days Sales Outstanding | - | - | - | - | - | - | - |
| Inventory | 0 | -6K | 3.01M | -90K | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - |
| Other Current Assets | 6K | 11K | 10K | 47K | 119K | 0 | 0 |
| Total Non-Current Assets | 0 | 0 | 82K | 85.82M | 62.21M | 34.05M | 2.25M |
| Property, Plant & Equipment | 0 | 0 | 82K | 97K | 1.07M | 748K | 620K |
| Fixed Asset Turnover | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 85.72M | 61.14M | 33.3M | 0 |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 1.63M |
| Total Assets | 504K▲ 0% | 5.91M▲ 1073.0% | 279.92M▲ 4634.8% | 254.36M▼ 9.1% | 226.3M▼ 11.0% | 188.27M▼ 16.8% | 288.23M▲ 53.1% |
| Asset Turnover | - | - | - | - | - | - | - |
| Asset Growth % | - | 1073.02% | 4634.84% | -9.13% | -11.03% | -16.8% | 53.09% |
| Total Current Liabilities | 104K | 246K | 2.75M | 4.55M | 6.7M | 8.95M | 8.38M |
| Accounts Payable | 93K | 1K | 883K | 1.87M | 0 | 0 | 0 |
| Days Payables Outstanding | - | - | - | - | - | - | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 343K | 255K | 365K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 168K | 312K | 6.36M | 8.7M | 8.02M |
| Current Ratio | 4.85x | 24.03x | 101.80x | 37.07x | 24.49x | 17.23x | 34.13x |
| Quick Ratio | 4.85x | 24.06x | 100.70x | 37.09x | 24.49x | 17.23x | 34.13x |
| Cash Conversion Cycle | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 0 | 0 | 1.87M | 631K | 369K | 147K |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 631K | 369K | 147K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 104K | 246K | 2.75M | 4.55M | 7.33M | 9.32M | 8.53M |
| Total Debt | 0 | 0 | 0 | 0 | 974K | 624K | 512K |
| Net Debt | -498K | -5.89M | -276.78M | -165.96M | -77.45M | -100.17M | -245.74M |
| Debt / Equity | - | - | - | - | 0.00x | 0.00x | 0.00x |
| Debt / EBITDA | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - |
| Interest Coverage | - | - | -1021.44x | - | -49.13x | -54.27x | -131.05x |
| Total Equity | 400K▲ 0% | 5.67M▲ 1316.5% | 277.18M▲ 4791.9% | 249.82M▼ 9.9% | 218.97M▼ 12.3% | 178.95M▼ 18.3% | 279.7M▲ 56.3% |
| Equity Growth % | - | 1316.5% | 4791.9% | -9.87% | -12.35% | -18.28% | 56.3% |
| Book Value per Share | 0.01 | 0.19 | 5.33 | 4.80 | 4.21 | 3.44 | 4.58 |
| Total Shareholders' Equity | 400K | 5.67M | 277.18M | 249.82M | 218.97M | 178.95M | 279.7M |
| Common Stock | 801K | 871K | 1.3M | 1.3M | 1.3M | 1.3M | 1.55M |
| Retained Earnings | -389K | -835K | -10.04M | -32.49M | -67.94M | -106.45M | -154.43M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -12K | 200K | -5.54M | -10.44M | -5.86M | -7.37M | 1.52M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
GHRS Cash Flow Statement
GH Research PLC (GHRS) cash flow — operating, investing & free cash flow history
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -289K | -330K | -15.28M | -26.2M | -33.34M | -42.28M | -43.55M |
| Operating CF Margin % | - | - | - | - | - | - | - |
| Operating CF Growth % | - | -14.19% | -4531.21% | -71.43% | -27.24% | -26.84% | -3% |
| Net Income | -310K | -446K | -9.2M | -22.46M | -35.59M | -38.96M | -48.26M |
| Depreciation & Amortization | 0 | 0 | 19K | 47K | 315K | 315K | 335K |
| Stock-Based Compensation | 0 | 0 | 366K | 1.67M | 2.29M | 1.17M | 0 |
| Deferred Taxes | 0 | 0 | -5.92M | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 0 | 0 | 9K | -7.62M | -2M | -5M | 7.46M |
| Working Capital Changes | 21K | 116K | -559K | 2.16M | 1.65M | 188K | -3.09M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Investing | 0 | 0 | -104K | -84.69M | -54.1M | 65.14M | 46.17M |
| Capital Expenditures | 0 | 0 | -104K | -67K | -100K | -49K | -121K |
| CapEx % of Revenue | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 797K | 5.5M | 286.45M | 0 | -204K | -304K | 139.65M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | -219K | -304K | 0 |
| Equity Issued (Net) | 797K | 5.5M | 309.2M | 0 | 15K | 0 | 139.85M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | -22.75M | 0 | 0 | 0 | -197K |
| Net Change in Cash | 498K▲ 0% | 5.4M▲ 983.7% | 270.88M▲ 4919.1% | -110.82M▼ 140.9% | -87.53M▲ 21.0% | 22.37M▲ 125.6% | 145.46M▲ 550.2% |
| Free Cash Flow | -289K▲ 0% | -330K▼ 14.2% | -15.39M▼ 4562.7% | -26.27M▼ 70.7% | -33.44M▼ 27.3% | -42.33M▼ 26.6% | -43.67M▼ 3.2% |
| FCF Margin % | - | - | - | - | - | - | - |
| FCF Growth % | - | -14.19% | -4562.73% | -70.7% | -27.3% | -26.61% | -3.16% |
| FCF per Share | -0.01 | -0.01 | -0.30 | -0.50 | -0.64 | -0.81 | -0.72 |
| FCF Conversion (FCF/Net Income) | 0.93x | 0.74x | 1.66x | 1.17x | 0.94x | 1.09x | 0.90x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
GHRS Key Ratios
GH Research PLC (GHRS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -77.5% | -14.7% | -6.51% | -8.52% | -15.18% | -19.58% | -21.04% |
| Return on Invested Capital (ROIC) | - | - | -13323.53% | -54.39% | -27.43% | -34.26% | -80.72% |
| Debt / Equity | - | - | - | - | 0.00x | 0.00x | 0.00x |
| Interest Coverage | - | - | -1021.44x | - | -49.13x | -54.27x | -131.05x |
| FCF Conversion | 0.93x | 0.74x | 1.66x | 1.17x | 0.94x | 1.09x | 0.90x |
GHRS Frequently Asked Questions
GH Research PLC (GHRS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
GH Research PLC (GHRS) grew revenue by 0.0% over the past year. Growth has been modest.
GH Research PLC (GHRS) reported a net loss of $48.3M for fiscal year 2025.
Dividend & Returns
GH Research PLC (GHRS) has a return on equity (ROE) of -21.0%. Negative ROE indicates the company is unprofitable.
GH Research PLC (GHRS) had negative free cash flow of $44.4M in fiscal year 2025, likely due to heavy capital investments.
Explore More GHRS
GH Research PLC (GHRS) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates